Andrew Brunner

Feb 27, 2024 | newsbreak.com | Andrew Brunner

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy

Jan 4, 2024 | nature.com | Shai Shimony |Andrew Brunner |Daniel DeAngelo

AbstractAdolescents and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face worse outcomes than children. While pediatric-inspired protocols have improved outcomes, the ability of patients to complete these intensive regimens and the reasons for discontinuation are unknown. We analyzed a cohort of 332 AYA patients (aged 15–49 years) and 1159 children (aged 1–14 years) with Ph-negative ALL treated on DFCI consortium protocols.

Aug 3, 2023 | onclive.com | Rami D. Komrokji |Andrew Brunner |Hetty Carraway |Yazan Madanat |Amer M Zeidan

EP: 1.Diagnosing Myelodysplastic Syndromes (MDS) EP: 2.Risk Stratification of MDS EP: 3.First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia EP: 4.Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia EP: 5.Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia EP: 6.Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia EP: 7.Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia EP: 8.Treatment...

Jul 28, 2023 | onclive.com | Rami D. Komrokji |Andrew Brunner |Hetty Carraway |Yazan Madanat |Amer M Zeidan

Luspatercept for Lower-Risk MDS: Data From the COMMANDS TrialRami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

Jul 28, 2023 | onclive.com | Rami D. Komrokji |Andrew Brunner |Hetty Carraway |Yazan Madanat |Amer M Zeidan

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.